WASHINGTON, Oct. 2, 2017 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that
data from the results of the Phase II study of tradipitant in
atopic dermatitis will be presented at the 9th World Congress of
Itch in Wroclaw Poland as a late breaking entry in the scientific
poster forum on October 16 and 17.
On September 13, 2017, Vanda
announced that tradipitant improved both itch and disease severity
in patients with atopic dermatitis.
About Atopic Dermatitis and Chronic Pruritus
Atopic dermatitis is a chronic, relapsing inflammatory skin
disorder characterized by the symptom of intense and persistent
pruritus or itch. Other clinical features include erythema,
excoriation, edema, lichenification, oozing and xerosis.
Atopic dermatitis is a common skin disorder affecting millions
of people worldwide. Currently there are very few safe systemic
treatments available for atopic dermatitis, representing a
significant unmet medical need in this population.
About the Neurokinin-1 Receptor and Substance P
The NK-1R is expressed throughout different tissues of the body,
with major activity found in neuronal tissue. SP and NK-1R
interactions in neuronal tissue regulate neurogenic inflammation
locally and the pain perception pathway through the central nervous
system. Other tissues, including endothelial cells and immune
cells, have also exhibited SP and NK-1R activity (2). The
activation of NK-1R by the natural ligand SP is involved in
numerous physiological processes, including the perception of pain,
behavioral stressors, cravings and the processes of nausea and
vomiting (1,2,3). An inappropriate over-expression of SP, either in
nervous tissue or peripherally, could result in pathological
conditions such as substance dependence, anxiety, nausea/vomiting
and pruritus (1,2,3,4). An NK-1R antagonist may possess the ability
to reduce this over-stimulation of the NK-1R, and as a result
address the underlying pathophysiology of the symptoms in these
conditions.
About Tradipitant
Tradipitant is an NK-1R antagonist licensed by Vanda from Eli
Lilly and Company (Lilly) in 2012. Tradipitant is currently in
clinical development for atopic dermatitis and gastroparesis. The
patent describing tradipitant as a new chemical entity is expected
to expire in the United States in
June 2029 based on an anticipated
Hatch-Waxman patent term extension. Tradipitant is an
investigational drug that is not currently approved for use in any
indication.
About Vanda
Vanda is a global biopharmaceutical company focused on the
development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of
patients. For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.
Abbreviations
NK-1R
Neurokinin-1 Receptor
SP
Substance P
References
1. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C,
Peng X, Keilbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M.
Neurokinin 1 receptor antagonism as a possible therapy for
alcoholism. Science. 2008; 319(5869):1536-9.
2. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, et al.
Tachykinins and tachykinin receptors: structure and activity
relationships. Current Medicinal Chemistry. 2004;11:2045-2081.
3. Hargreaves R, Ferreira JC, Hughes D, Brands J, Hale J,
Mattson B, Mill S. Development of aprepitant, the first
neurokinin-1 receptor antagonist for the prevention of
chemotherapy-induced nausea and vomiting. Annals of the New York
Academy of Sciences. 2011; 1222:40-48.
4. Staender S, Weisshaar E, Luger A. Neurophysiological and
neurochemical basis of modern pruritus treatment. Experimental
Dermatology. 2007;17:161-69.
FORWARD LOOKING STATEMENTS
Various statements in this release are "forward-looking
statements" under the securities laws. Forward-looking statements
are based upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking statements include, among
others: the ability of NK-1R inhibition to provide benefit in the
treatment of atopic dermatitis; Vanda's ability to obtain patent
term extension under the Hatch-Waxman Act for the new chemical
entity patent covering tradipitant and other factors that are
described in the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of Vanda's annual report on Form 10-K for the fiscal year
ended December 31, 2016 and quarterly report on Form 10-Q
for the quarter ended June 30, 2017, which are on file with
the SEC and available on the SEC's website
at www.sec.gov. In addition to the risks described above and
in Vanda's annual report on Form 10-K and quarterly reports on Form
10-Q, other unknown or unpredictable factors also could affect
Vanda's results. There can be no assurance that the actual results
or developments anticipated by Vanda will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Therefore, no assurance can
be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this release is
provided only as of the date of this release, and Vanda undertakes
no obligation, and specifically declines any obligation, to update
or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate Contact:
Jim
Kelly
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-to-present-tradipitant-phase-ii-atopic-dermatitis-data-at-world-congress-of-itch-300529043.html
SOURCE Vanda Pharmaceuticals Inc.